For the Quarter Ending March 2026
Cefuroxime Prices in North America
- In the USA, the Cefuroxime Price Index fell by 2.01% quarter-over-quarter, reflecting abundant imports recently.
- The average Cefuroxime price for the quarter was approximately USD 91658.33/MT, reflecting softer import costs.
- Cefuroxime Spot Price remained range-bound as distributors drew from comfortable inventories, limiting spot buying pressure currently.
- Cefuroxime Price Forecast shows monthly variability, modest firmer bias as freight and audits raise costs.
- Cefuroxime Production Cost Trend reflects higher logistics and compliance expenses, increasing delivered-cost pressure for importers.
- Cefuroxime Demand Outlook is stable across hospitals and retail, tenders and utilization limit upside pressure.
- Cefuroxime Price Index firmed in March as freight spikes and tighter compliant output contracted volumes modestly.
- Exports from China and India remained intact, exporters balanced offers protecting margins amid US demand.
Why did the price of Cefuroxime change in March 2026 in North America?
- March freight increases raised landed costs, prompting exporters to pass higher logistics charges to buyers.
- Environmental inspections limited surplus 7-ACA output, tightening delivered supply and reducing distributors' buffer inventories slightly.
- Stable hospital procurement and tenders restrained spot buying, moderating downward price pressure despite cost rises.
Cefuroxime Prices in APAC
- In China, the Cefuroxime Price Index fell by 1.97% quarter-over-quarter, reflecting modest bearish pressure overall.
- The average Cefuroxime price for the quarter was approximately USD 91550.00/MT across FOB export offers.
- Cefuroxime Spot Price remained range-bound as exporters held offers amid ample inventories and operating rates.
- Cefuroxime Price Forecast indicates mild recovery as downstream formulators replenish ahead of second-quarter production schedules.
- Cefuroxime Production Cost Trend stayed flat with stable feedstock and energy tariffs, limiting cost pressure.
- Cefuroxime Demand Outlook improved modestly in March driven by hospital tenders and export replenishment from markets.
- Cefuroxime Price Index reflected monthly variation as routine logistics and no environmental shutdowns maintained consistent supply.
- Port activity and inventory management kept export flows steady, constraining volatility despite regional procurement seasonality.
Why did the price of Cefuroxime change in March 2026 in APAC?
- Hospital tender finalizations supported demand, absorbing exportable volumes and lifting realized FOB offers modestly in March.
- Stable feedstock and unchanged energy tariffs prevented production-cost inflation, maintaining producer margins and price stability.
- Normal port operations and three-week inventories reduced logistics disruption risk, encouraging systematic replenishment by buyers.
Cefuroxime Prices in Europe
- In Germany, the Cefuroxime Price Index fell by 1.95% quarter-over-quarter, reflecting ample Asian export availability.
- The average Cefuroxime price for the quarter was approximately USD 91663.33/MT, supporting modest seller resistance.
- Ample Asian flows pressured the Cefuroxime Spot Price, keeping Hamburg landed values soft to offers.
- The Cefuroxime Price Forecast shows modest strengthening as buyers cautiously rebuild inventories for hospital tenders.
- Elevated freight and energy influenced the Cefuroxime Production Cost Trend, constraining exporters' margin recovery mildly.
- Stable hospital contracts and stewardship limits define the Cefuroxime Demand Outlook, keeping incremental buying subdued.
- Inventory cushions and Asian exports restrained the Cefuroxime Price Index, limiting seller leverage in negotiations.
- Logistics delays and early tender calls tightened availability, prompting spot premiums and firmer March CFRs.
Why did the price of Cefuroxime change in March 2026 in Europe?
- Reduced Asian run-rates, diverted plant capacity tightened arrivals, creating immediate supply pressure and spot premiums.
- A firmer euro softened dollar-denominated offers in euro terms, offsetting headline cost increases for importers.
- Extended transit times and isolated rail disruptions increased urgency for replenishment, elevating demand, CFR quotes.
For the Quarter Ending December 2025
Cefuroxime Prices in North America
- In USA, the Cefuroxime Price Index rose by 1.04% quarter-over-quarter, reflecting marginal import cost increases.
- The average Cefuroxime price for the quarter was approximately USD 131855.00/MT, reflecting landed-cost change modestly.
- Stable imports kept the Cefuroxime Spot Price steady while margins tracked Cefuroxime Production Cost Trend.
- Cefuroxime Price Forecast shows narrow ranges as freight reductions offset modest upstream input firmness recently.
- Seasonal restocking supports the Cefuroxime Demand Outlook and keeps the Cefuroxime Price Index broadly steady.
- Inventory remained moderate at wholesalers, limiting upside for Cefuroxime Spot Price despite importer allocations currently.
- Export supply discipline from Asia and FDA oversight stabilized volumes, supporting the Cefuroxime Price Index.
- Manufacturers and importers expect measured procurement, aligning with the Cefuroxime Price Forecast and stable demand.
Why did the price of Cefuroxime change in December 2025 in North America?
- Reduced Trans-Pacific freight and steady Asian API exports lowered landed costs, tempering upward pressure seasonally.
- Chinese environmental inspections trimmed some export offers while West Coast port operations preserved arrivals timely.
- Hospital restocking and GPO pricing caps balanced procurement, sustaining marginal price increases without triggering volatility.
Cefuroxime Prices in APAC
- In China, the Cefuroxime Price Index rose by 1.5% quarter-over-quarter, supported by export procurement demand.
- The average Cefuroxime price for the quarter was approximately USD 132333.33/MT, reflecting export and domestic contracts.
- Cefuroxime Spot Price remained pressured in December as ample export-oriented supply slightly outpaced incremental overseas enquiry.
- Cefuroxime Price Forecast signals narrow, mildly soft trading into early quarter absent significant demand improvement.
- Cefuroxime Production Cost Trend was stable as 7-ACA availability and energy tariffs exerted minimal upward pressure.
- Cefuroxime Demand Outlook remains steady with hospital tender caps limiting domestic upside while supporting exports.
- Cefuroxime Price Index showed marginal quarterly gain while inventories rose and exporters trimmed offers defensively.
- Major Chinese plants maintained sub-seventy percent operating rates, constraining volatility while keeping export supply adequate.
Why did the price of Cefuroxime change in December 2025 in APAC?
- Exports outpaced incremental enquiries in December, creating mild oversupply pressure on FOB quotations and offers.
- Stable 7-ACA feedstock and unchanged energy tariffs limited production cost increases, reducing upward price momentum.
- Port operations remained fluid and currency movements provided no advantage, prompting exporters to concede discounts.
Cefuroxime Prices in Europe
- In Germany, the Cefuroxime Price Index rose by 1.47% quarter-over-quarter, reflecting marginal import cost increases.
- The average Cefuroxime price for the quarter was approximately USD 132418.33/MT, according to trade statistics.
- Cefuroxime Spot Price remained muted in December due to moderate inventories and reduced spot buying.
- Cefuroxime Price Forecast indicates range-bound near-term pricing, contingent on logistics and stewardship-driven hospital procurement patterns.
- Cefuroxime Production Cost Trend rose from higher 7-ACA and energy-related compliance costs, pressuring export offers.
- Cefuroxime Demand Outlook remains seasonally supportive from hospital tenders while stewardship protocols limit volume growth.
- Cefuroxime Price Index reflected import-cost pass-through, freight uplifts and comfortable inventories, preventing upward pricing moves.
- Asian exporters maintained operating rates, prioritised US orders, narrowing German availability and supporting CFR Hamburg.
Why did the price of Cefuroxime change in December 2025 in Europe?
- Balanced import flows and unchanged Asian offers kept landed costs stable, limiting December price pressure.
- Hospital purchasers covered fourth-quarter needs, reducing spot inquiries and weakening sellers' demand for higher premiums.
- Freight and logistics eased in Hamburg, while comfortable wholesaler stocks reduced urgency, nudging prices lower.
For the Quarter Ending September 2025
North America
- In USA, the Cefuroxime Price Index fell by 3.56% quarter-over-quarter, reflecting exporter discounting and inventory.
- The average Cefuroxime price for the quarter was approximately USD 130496.67/MT, reflecting elevated landed costs.
- Cefuroxime Spot Price softened as US buyers reduced orders, leaving elevated inventories and strained liquidity.
- Cefuroxime Price Forecast points to volatility, with potential stabilization as replenishment increases and inventories normalize.
- Cefuroxime Production Cost Trend eased due to lower upstream input prices, supporting exporter margin recovery.
- Cefuroxime Demand Outlook remains steady, anchored by hospital and clinical usage despite conservative pharmaceutical procurement.
- Freight rate declines and episodic congestion created landed cost signals, supporting the Cefuroxime Price Index.
- Scheduled maintenance and seasonal procurement could tighten supply briefly, mildly lifting the Cefuroxime Price Index.
Why did the price of Cefuroxime change in September 2025 in North America?
- Oversupply from major Asian exporters pressured discounts, increasing US inventories and sustaining downward price pressure.
- Falling freight rates followed by port congestion created inconsistent landed costs, confusing importer procurement decisions.
- Buyer caution amid tariff uncertainties and high inventories suppressed spot demand, limiting upward price momentum.
APAC
- In China, the Cefuroxime Price Index fell by 3.47% quarter-over-quarter, driven by oversupply and weak demand.
- The average Cefuroxime price for the quarter was approximately USD 130400.00/MT, reflecting subdued domestic demand.
- Cefuroxime Spot Price rallied briefly during operational disruptions, yet overall Price Index remained subdued amid inventory overhang.
- Cefuroxime Production Cost Trend shows downward pressure from cheaper raw materials, partly offset by elevated logistics expenses.
- Cefuroxime Demand Outlook remains weak as PMI contraction and export tariffs suppressed new orders and downstream offtake.
- Cefuroxime Price Forecast suggests modest volatility with intermittent upticks due to maintenance and occasional forward buying.
- High inventories and tariff-driven export disruptions pressured domestic margins, influencing the Cefuroxime Price Index trajectory negatively.
- Major producer maintenance temporarily tightened supply, but smaller manufacturers increased volumes, keeping spot markets and Price Index soft.
Why did the price of Cefuroxime change in September 2025 in APAC?
- Temporary plant maintenance reduced available exports while domestic inventories remained elevated, creating mixed supply signals.
- Logistics disruptions and port congestion increased distribution costs, contributing to localized tighter supply and upward price pressure.
- Weak pharmaceutical demand, PMI contraction and high inventories suppressed selling prices despite periodic forward buying and short-term restocking.
Europe
- In Germany, the Cefuroxime Price Index fell by 3.51% quarter-over-quarter, driven by ample inventories nationally.
- The average Cefuroxime price for the quarter was approximately USD 130503.67/MT, according to reported data.
- Cefuroxime Spot Price volatility eased as German distributors prioritized inventory liquidation, compressing Price Index movements.
- Cefuroxime Production Cost Trend softened amid lower energy and input costs, supporting margins for manufacturers.
- Cefuroxime Demand Outlook for hospitals remained subdued, with buyers exercising cautious procurement and prioritizing inventories.
- Cefuroxime Price Forecast indicates modest near-term weakness, with slight recovery potential as logistics gradually normalize.
- Elevated inventories and muted export demand kept the Cefuroxime Price Index anchored despite logistical pressures.
- Chinese supply remained ample, while producers offered discounted volumes, exerting downward pressure on spot markets.
Why did the price of Cefuroxime change in September 2025 in Europe?
- Persistent inventory overhang from earlier procurement waves reduced spot purchases, pressuring prices downward in September.
- Shipping delays and elevated logistics costs supported prices, but delayed peak surcharges limited import-driven spikes.
- Subdued downstream demand and cautious procurement strategies by hospitals and manufacturers constrained upward price momentum.
For the Quarter Ending June 2025
North America
- Q2 2025 saw a mixed trajectory in North American Cefuroxime spot prices, starting with a significant decline in April (-4.90%), a sharp rebound in May (+0.19%), and stabilizing with a slight downturn in June (-0.23%)—averaging roughly a 1.65% net downward fluctuation across the quarter.
- Prices in June 2025 declined notably due to oversupply from increased production in China and India, coupled with cautious procurement owing to tariff uncertainty.
- April’s price drop was driven by weak demand and trade policy uncertainties, including high U.S. tariffs on Chinese imports that disrupted trade flows and increased domestic inventories. In May, a tariff suspension triggered a surge in freight demand, causing logistical bottlenecks and temporary price hikes. June saw aggressive exporter price cuts amid inventory gluts and tariff risks.
- Consistently modest demand in April was followed by strong pharmaceutical procurement in May to rebuild safety stocks amid trade tensions. June demand remained stable but subdued due to buyers relying on existing stocks amid ongoing uncertainties and logistical challenges.
- U.S. tariffs, peaking at 145% on Chinese pharmaceutical imports from April 2025, influenced production costs and pricing strategies, pressuring manufacturers to balance supply and demand.
- High ocean freight costs and port congestion contributed to price volatility within Q2. May's freight surge was countered by improved shipping capacity but persistent delays.
- Continued reliance on Cefuroxime for bacterial infections reinforced baseline demand, especially in hospital and outpatient settings, despite market pricing pressures.
- Given tariff complexities and supply gluts, price recovery may be limited in the short term; volatility is likely to persist through Q3 2025.
- Rising production costs, driven by regulatory compliance and import tariffs, challenged manufacturers, but supply capacity remained sufficient to meet demand.
- Cautious buyer behavior amid macroeconomic uncertainty and trade policies dominated, reinforcing a buyer's market for Cefuroxime APIs in North America.
Asia Pacific
- Cefuroxime price index in APAC displayed a generally stable to slight downward trend with April (-4.93%), a minor uptick in May (+0.19%), and a small decrease in June (-0.18%). The quarterly average fluctuation stood near 1.64% down.
- June saw notable price decreases due to intense domestic price competition, PPI deflation (-3.6% YoY), and persistent overcapacity, particularly in China, the region's major producer.
- April’s price pressures stemmed from reduced domestic consumption and export challenges from U.S.-China tariffs. May temporarily reversed this with strong export demand and logistics strain due to tariff reprieves and order surges. Maintenance shutdowns and shifting production shares among manufacturers influenced June’s supply dynamics.
- April and June saw subdued demand linked to macroeconomic weakness and industry overcapacity, while May witnessed a resurgence in global buying, particularly from the U.S. in anticipation of tariff expirations.
- The U.S.-China trade tensions, with tariffs up to 245%, constrained export flow and incentivized aggressive pricing among Chinese producers to maintain competitiveness internationally.
- May’s sharp rise in spot container shipping rates (+27%) driven by increased transpacific cargo flows contributed to upward price pressure.
- Despite rising logistics costs, overall manufacturing costs faced downward pressure due to overcapacity and price wars among producers.
- Chinese government concern about excessive price competition remains, but corrective measures are limited, sustaining volatile pricing.
- APAC is expected to face ongoing price pressure until demand recovers and supply balances, with possible stabilization after the temporary tariff reprieve ends in August 2025.
- Pharmaceutical applications dominate demand, but subdued consumer purchasing power and manufacturing sluggishness continue to weigh on spot price momentum despite Cefuroxime’s clinical importance.
Europe
- The European Cefuroxime market exhibited a generally downward trend with prices dropping sharply in April (-4.90%), a mild increase in May (+0.18%), and another decline in June (-0.25%), equating to an average 1.65% overall decrease for Q2.
- June's price drop was driven by ample inventories from early acquisitions, low inflation, and logistical constraints delaying spot market activity and purchase urgency.
- April and May saw oversupply due to diverted Chinese shipments from the U.S. market and front-loaded European stocking before public holidays, stressing inventories. Freight congestion and port bottlenecks in Northern Europe added delivery delays.
- April and June demand remained cautious and inventory-driven rather than consumption-led. Pharmaceutical and secondary downstream sectors awaited market clarity, limiting new order volumes.
- The temporary removal of U.S. tariffs diverted Asian exports towards Europe, swelling local supply and exerting downward pressure on prices.
- Low monthly inflation (~2.0% YoY in June) and soft PMI readings (50.4 in June) suggested a cooling economy dampening buying enthusiasm.
- Port operational issues in Hamburg, Rotterdam, and Antwerp caused persistent delays, compounding supply-demand mismatches and price weakness.
- Stability in API supply from Asia was maintained, but slow uptake and inventory liquidation strategies dominated market behavior.
- Prices are expected to remain subdued in the near term, with potential for stabilization only after inventory normalizations and logistical improvements.
- Pharmaceutical buyers, hospitals, and generic manufacturers focused on inventory rationalization rather than expansion, moderating demand and supporting a soft price environment.
